Forbeli s.r.o.

At Forbeli s.r.o. in Prague, the clinical research focus is centered on Nervous System Diseases, with studies exploring both seizure disorders and cognitive decline. The trials aim to evaluate new treatment options, assess safety and tolerability, and better understand how therapies may improve symptom control and daily function.

• Epilepsy research focused on improving seizure control and treatment effectiveness
• Focal onset seizures studies assessing add-on and long-term therapy options
• Primary generalized tonic-clonic seizures trials evaluating sustained treatment benefit and safety
• Alzheimer’s disease research examining potential therapies for mild cognitive impairment and early dementia

Overall, the site supports clinical trials that look at both seizure reduction and early intervention in Alzheimer’s disease, reflecting a strong interest in practical therapies for common neurological conditions.

The Neurologická ambulance at Forbeli s.r.o. is conducting research in epilepsy and related seizure disorders, including focal onset seizures and primary generalized tonic-clonic seizures. These studies are designed to test whether new therapies can reduce seizure frequency and improve long-term disease management.

• Testing new treatment approaches for focal-onset seizures
• Evaluating add-on therapy for people whose seizures remain difficult to control
• Assessing the safety and tolerability of longer-term seizure treatment

This area of research is especially relevant for patients living with ongoing seizures, as the trials aim to support better control, fewer attacks, and more reliable treatment options.

Another important area of work at this hospital/clinic is Alzheimer’s disease research, particularly in people with mild cognitive impairment or mild dementia. The trials are evaluating whether emerging therapies can help slow cognitive decline while remaining safe and tolerable for patients.

• Studying treatment options for mild dementia linked to Alzheimer’s disease
• Assessing safety and tolerability in early cognitive impairment
• Measuring whether therapy may improve or preserve everyday cognitive function

This research reflects a broader effort to improve care for people in the earlier stages of neurodegenerative disease, where effective intervention may have the greatest impact.